About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Future of Exosome-Based Nanotherapeutics Effective for Pneumonia Associated Acute Lung Injury.

Researchers

Aiping Zou, Yeqing Tao, Yuwen Wang, Yafang Li

Abstract

Severe pneumonia can progress to acute respiratory distress syndrome (ARDS), yet effective adjunctive therapies targeting host-mediated lung injury remain limited. Exosome-based nanotherapeutics have emerged as promising cell-free candidates capable of modulating multiple pathological processes. This narrative review examines their therapeutic mechanisms, delivery strategies, engineering advances, and translational challenges in pneumonia-associated lung injury. Preclinical studies suggest that extracellular vesicle (EV) preparations, frequently described as exosomes, may attenuate inflammatory responses, preserve alveolar-capillary barrier integrity, mitigate oxidative stress and regulated cell death, and promote tissue repair. However, most evidence derives from lipopolysaccharide-induced, sepsis-associated, and other non-infectious acute lung injury (ALI) models, whereas direct evidence from pathogen-confirmed pneumonia models remains limited. Although infectious and non-infectious lung injury share important pathological mechanisms, differences in pathogen clearance and host immune responses restrict direct extrapolation. Human evidence remains limited to early clinical investigations, and therapeutic efficacy has not been established. Major translational challenges include product heterogeneity, insufficient standardization and potency assessment, uncertain functional delivery, and unresolved questions regarding dosing, safety, and patient selection. Future development requires rigorous product characterization, optimized pulmonary delivery, infection-relevant preclinical validation, and well-designed clinical trials. Overall, exosome-based nanotherapeutics offer potential as adjunctive interventions, but their clinical utility in pneumonia-associated lung injury remains to be determined.
Source: PubMed (PMID: 43036701)View Original on PubMed